Fadi Farhat

Fadi Farhat


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2017 in The Oncologist
Verified
Journal Article
Closed access
PDF file
FFFadi Farhat
Fadi Farhat
ATAlfredo Torres
Alfredo Torres
WPWungki Park
Wungki Park
GLGilberto de Lima Lopes
Gilberto de Lima Lopes
RMRaja Mudad
Raja Mudad
SASimon Abi Aad
Simon Abi Aad
Biologic agents are currently the fastest emerging segment of drug expenditure. Unlike chemically synthesized small-molecule drugs, biologics are more complex, medicinal products produced by a living organism. They have become part of the standard of care in the treatment of a large variety of diseases, such as growth disorders, autoimmune diseases, cancer, cardiovascular illnesses, hemophilia, and rare genetic conditions, to name a few. Biosimilars, which are copies of biologics that are highly similar, were introduced in the market with an aim to offer efficacy that is not clinically different from the originator or reference product, at lower prices. We aim to clarify the concept of biosimilar, from definitions, history, market entry, challenges faced, and future evolution. For that purpose, we performed a literature search on the sites of the medicines regulatory agencies and PubMed from 1990 to 2014 with the keywords “biosimilars,” “market,” and “regulatory.” In 2006, the first biosimilar, somatropin [rDNA origin], was marketed and led the way for biosimilar drug manufacturing. As a result, manufacturers have entered a diversified competition, facing challenges in manufacturing these complex agents, such as immunogenicity and efficiency. Biosimilars are set to evolve differently in various markets, namely the U.S., Japan, the European Union, and the “pharmerging” economies. Implications for Practice: This article highlights the importance of biosimilars, as a cost-cutting strategy, in the delivery of state-of-the-art health care in developing countries, at a fraction of what a reference biological agent would cost.

13 June 2013 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
FFFadi Farhat
Fadi Farhat
WHWissam Houhou
Wissam Houhou
The search for innovative therapeutic agents in non-small cell lung cancer (NSCLC) has witnessed a swift evolution. The number of targeted drugs that can improve patient outcomes with an acceptable safety profile is steadily increasing. In this review, we highlight current drugs that have already been approved or are under evaluation for the treatment of patients with NSCLC, either in monotherapy or combined therapy for both the first- and second-line settings. Experience with drugs targeting the vascular endothelial growth factor and its receptor, as well as the epidermal growth factor receptor is summarized. Moreover, we provide an overview of more novel targets in NSCLC and initial experience with the respective therapeutic agents.

28 September 2017 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
NFNajla Fakhruddin
Najla Fakhruddin
Hisham BahmadHisham Bahmad
Hisham Bahmad
TATarek Aridi
Tarek Aridi
YYYara Yammine
Yara Yammine
RMRami Mahfouz
Rami Mahfouz
FFFadi Farhat
Fadi Farhat
Hepatoid adenocarcinoma of the stomach (HAS) is a rare aggressive tumor with hepatocellular differentiation. HAS often produces alpha fetoprotein (AFP) and metastasizes to the lymph nodes and the liver. Molecular studies revealed Her2 amplification and overexpression, association with p53 mutations, but no association with KRAS mutations. EGFR and BRAF mutations have not yet been evaluated in hepatoid carcinoma of the stomach so far. Hereby, we present a case of a 41-year-old female patient with HAS with high AFP level and liver metastases. Molecular analysis revealed Her2 overexpression by immunohistochemistry (IHC), but no EGFR, KRAS, or BRAF mutations were detected. The patient underwent chemotherapy type DCX (docetaxel, cisplatinum, and capecitabine) every 3 weeks with partial response after two cycles, maintained for eight cycles, and then was on maintenance therapy with trastuzumab for 7 months before relapsing and dying 18 months from the day of diagnosis. Conclusively, HAS may be misdiagnosed as hepatocellular carcinoma; therefore, it should be considered in the differential diagnosis of multiple hepatic nodules with high AFP and no history of hepatitis, liver fibrosis or cirrhosis.

9 October 2008 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
RHRachid Haidar
Rachid Haidar
SSSaid Sagghieh
Said Sagghieh
SMSamar Muwakitt
Samar Muwakitt
GMGhina Mumtaz
Ghina Mumtaz
SASamir Akel
Samir Akel
MAMiguel Abboud
Miguel Abboud

13 October 2009 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
HDHanane A. Dahoui
Hanane A. Dahoui
MHMunya N. Hayek
Munya N. Hayek
PNPaul Nietert
Paul Nietert
MAMariam T. Arabi
Mariam T. Arabi
SMSamar A. Muwakkit
Samar A. Muwakkit
MAMiguel Abboud
Miguel Abboud

23 May 2018 in Pharmacogenomics
Verified
Journal Article
Closed access
Said El ShamiehSaid El Shamieh
Said El Shamieh
FSFatima Saleh
Fatima Saleh
SMSalim Moussa
Salim Moussa
JKJoseph Kattan
Joseph Kattan
FFFadi Farhat
Fadi Farhat
Triple-negative breast cancer (TNBC) is characterized by its aggressive behavior, metastasis and lack of targeted therapies. Herein, we discuss the clinical, histopathological and genetic profile of a woman diagnosed with TNBC. Since the patient had no durable response to chemotherapy, a genetic profiling was carried out. Next-generation sequencing analysis of 592 genes showed a missense mutation, p.E545A in PIK3CA, thus the patient was started on the mTOR inhibitor everolimus, in combination with exemestane, which controlled her pain; however, the disease progressed aggressively. More importantly, next-generation sequencing analysis showed a RICTOR gene amplification (eight copies) suggesting that RICTOR promotes the genesis of TNBC. We conclude that determining regulators of RICTOR and furthermore, their inhibitors might decrease cancer cells proliferation rate in patients with TNBC.